Your browser doesn't support javascript.
loading
Biochemical Relapse for Prostate Cancer Following Radical Prostatectomy: Salvage Radiotherapy Without HormonalTherapy
Fêde, Ângelo B S; Jacinto, Alexandre Arthur; Fagundes, Lívia A; Pellizzon, Antonio Cássio Assis; Novaes, Paulo Eduardo Ribeiro dos Santos; Arruda, Gustavo Viani; Castilho, Marcus Simões; Maia, Maria Aparecida Conte; Silva, Maria Letícia Gobo; Fogaroli, Ricardo César; Salvajoli, João Victor.
  • Fêde, Ângelo B S; Faculdade de Medicina do ABC. São Paulo. BR
  • Jacinto, Alexandre Arthur; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Fagundes, Lívia A; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Pellizzon, Antonio Cássio Assis; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Novaes, Paulo Eduardo Ribeiro dos Santos; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Arruda, Gustavo Viani; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Castilho, Marcus Simões; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Maia, Maria Aparecida Conte; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Silva, Maria Letícia Gobo; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Fogaroli, Ricardo César; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
  • Salvajoli, João Victor; Hospital do Câncer A. C. Camargo. Departamento de Radioterapia. São Paulo. BR
Appl. cancer res ; 26(1): 34-39, Jan.-Mar. 2006.
Article in English | LILACS, Inca | ID: lil-442322
ABSTRACT

Objectives:

This paper aims to study biochemical control, hormonal therapy-free survival, and prognostic factors related tosalvage radiation for prostate cancer patients submitted to radical prostatectomy (RP) without hormonal therapy (HT) before orduring radiation. Materials and

Methods:

from August 2002 to July 2004, 39 prostate cancer patients submitted to RPpresented biochemical failure after achieving PSA nadir (<0.2ng/ml). All patients were submitted to three-dimensional conformalexternal beam radiation therapy (3DC-EBRT) and no patients had received HT. Median age was 62 years, median preoperativePSA was 9.4ng/ml, median Gleason Score was 7. We defined PSA rise above 0.2 as biochemical failure after surgery. Median3DC-EBRT dose was 70Gy, and biochemical failure after EBRT was defined as three consecutive rises in PSA or a single risesufficient to trigger HT.

Results:

Biochemical non-evidence of disease (BNED) in 3 years was 72%. PSA doubling time (PSADT)lower than 4 months (p=0.04), and delay to salvage EBRT (p=0.05) were associated to worse chance of successful salvagetherapy. Late morbidity was acceptable.

Conclusion:

Expressive PSA control (72% BNED / 3years) could be achieved withsalvage radiotherapy in well-selected patients. The importance of PSADT was confirmed, and radiotherapy should be started asearly as possible. Follow-up is somewhat short, but it is possible to conclude that it is possible to achieve a long interval freefrom hormonal therapy with low rate of toxicity, avoiding or at least delaying morbidity related to hormonal treatment.radiotherapy
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Prostatectomy / Prostatic Neoplasms / Radiotherapy Type of study: Prognostic study Limits: Humans / Male Language: English Journal: Appl. cancer res Journal subject: Neoplasms Year: 2006 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculdade de Medicina do ABC/BR / Hospital do Câncer A. C. Camargo/BR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Prostatectomy / Prostatic Neoplasms / Radiotherapy Type of study: Prognostic study Limits: Humans / Male Language: English Journal: Appl. cancer res Journal subject: Neoplasms Year: 2006 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculdade de Medicina do ABC/BR / Hospital do Câncer A. C. Camargo/BR